Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.
Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, Liu MC, Iwata H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P. Adams S, et al. Among authors: cescon dw. Ann Oncol. 2019 Mar 1;30(3):405-411. doi: 10.1093/annonc/mdy518. Ann Oncol. 2019. PMID: 30475947 Free article. Clinical Trial.
Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages.
Kim H, Aliar K, Tharmapalan P, McCloskey CW, Kuttanamkuzhi A, Grünwald BT, Palomero L, Mahendralingam MJ, Waas M, Mer AS, Elliott MJ, Zhang B, Al-Zahrani KN, Langille ER, Parsons M, Narala S, Hofer S, Waterhouse PD, Hakem R, Haibe-Kains B, Kislinger T, Schramek D, Cescon DW, Pujana MA, Berman HK, Khokha R. Kim H, et al. Among authors: cescon dw. Cell Rep. 2023 Oct 31;42(10):113256. doi: 10.1016/j.celrep.2023.113256. Epub 2023 Oct 16. Cell Rep. 2023. PMID: 37847590 Free article.
Ionizable Drugs Enable Intracellular Delivery of Co-Formulated siRNA.
Slaughter KV, Donders EN, Jones MS, Sabbah SG, Elliott MJ, Shoichet BK, Cescon DW, Shoichet MS. Slaughter KV, et al. Among authors: cescon dw. Adv Mater. 2024 Oct;36(41):e2403701. doi: 10.1002/adma.202403701. Epub 2024 Aug 15. Adv Mater. 2024. PMID: 39148215
The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers.
Kazandjian S, Rousselle E, Dankner M, Cescon DW, Spreafico A, Ma K, Kavan P, Batist G, Rose AAN. Kazandjian S, et al. Among authors: cescon dw. Cancers (Basel). 2024 Jan 19;16(2):445. doi: 10.3390/cancers16020445. Cancers (Basel). 2024. PMID: 38275886 Free PMC article.
Identification of KIFC1 as a putative vulnerability in lung cancers with centrosome amplification.
Zhang C, Wu BZ, Di Ciano-Oliveira C, Wu YF, Khavkine Binstock SS, Soria-Bretones I, Pham NA, Elia AJ, Chari R, Lam WL, Bray MR, Mak TW, Tsao MS, Cescon DW, Thu KL. Zhang C, et al. Among authors: cescon dw. Cancer Gene Ther. 2024 Oct;31(10):1559-1570. doi: 10.1038/s41417-024-00824-1. Epub 2024 Aug 24. Cancer Gene Ther. 2024. PMID: 39179685 Free PMC article.
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Lin CC, Chang TC, Wang Y, Guo L, Gao Y, Bikorimana E, Lemoff A, Fang YV, Zhang H, Zhang Y, Ye D, Soria-Bretones I, Servetto A, Lee KM, Luo X, Otto JJ, Akamatsu H, Napolitano F, Mani R, Cescon DW, Xu L, Xie Y, Mendell JT, Hanker AB, Arteaga CL. Lin CC, et al. Among authors: cescon dw. Res Sq [Preprint]. 2023 Jul 10:rs.3.rs-2966905. doi: 10.21203/rs.3.rs-2966905/v1. Res Sq. 2023. Update in: Nat Commun. 2024 Mar 13;15(1):2287. doi: 10.1038/s41467-024-46495-2 PMID: 37502925 Free PMC article. Updated. Preprint.
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J. Adams S, et al. Among authors: cescon dw. Ann Oncol. 2019 Mar 1;30(3):397-404. doi: 10.1093/annonc/mdy517. Ann Oncol. 2019. PMID: 30475950 Free article. Clinical Trial.
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).
Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, Ghai S, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S, Giesler A, Hakgor S, Jiang H, McGaha T, Brooks DG, Haibe-Kains B, Pugh TJ, Ohashi PS, Siu LL. Clouthier DL, et al. J Immunother Cancer. 2019 Mar 13;7(1):72. doi: 10.1186/s40425-019-0541-0. J Immunother Cancer. 2019. PMID: 30867072 Free PMC article. Clinical Trial.
135 results